# Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)

> **NCT01309633** · PHASE2 · COMPLETED · sponsor: **National University Hospital, Singapore** · enrollment: 80 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** 12.5mg sunitinib with Cisplatin and Gemcitabine
- **DRUG:** 25mg Sunitinib alternating with Cisplatin and Gemcitabine
- **DRUG:** 7.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine
- **DRUG:** 2.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine

## Key facts

- **NCT ID:** NCT01309633
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-02
- **Primary completion:** 2019-03-11
- **Final completion:** 2019-03-11
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2019-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01309633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01309633, "Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01309633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*